Literature DB >> 34354135

Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register.

Muhammad Osman1, Cari van Schalkwyk2, Pren Naidoo3, James A Seddon3,4, Rory Dunbar3, Sicelo S Dlamini5, Alex Welte2, Anneke C Hesseling3, Mareli M Claassens6,7.   

Abstract

In 2011, the South African HIV treatment eligibility criteria were expanded to allow all tuberculosis (TB) patients lifelong ART. The impact of this change on TB mortality in South Africa is not known. We evaluated mortality in all adults (≥ 15 years old) treated for drug-susceptible TB in South Africa between 2009 and 2016. Using a Cox regression model, we quantified risk factors for mortality during TB treatment and present standardised mortality ratios (SMR) stratified by year, age, sex, and HIV status. During the study period, 8.6% (219,618/2,551,058) of adults on TB treatment died. Older age, male sex, previous TB treatment and HIV infection (with or without the use of ART) were associated with increased hazard of mortality. There was a 19% reduction in hazard of mortality amongst all TB patients between 2009 and 2016 (adjusted hazard ratio: 0.81 95%CI 0.80-0.83). The highest SMR was in 15-24-year-old women, more than double that of men (42.3 in 2016). Between 2009 and 2016, the SMR for HIV-positive TB patients increased, from 9.0 to 19.6 in women, and 7.0 to 10.6 in men. In South Africa, case fatality during TB treatment is decreasing and further interventions to address specific risk factors for TB mortality are required. Young women (15-24-year-olds) with TB experience a disproportionate burden of mortality and interventions targeting this age-group are needed.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34354135     DOI: 10.1038/s41598-021-95331-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  21 in total

Review 1.  A systematic review of risk factors for death in adults during and after tuberculosis treatment.

Authors:  C J Waitt; S B Squire
Journal:  Int J Tuberc Lung Dis       Date:  2011-04-12       Impact factor: 2.373

2.  Are there differences in disease progression and mortality among male and female HIV patients on antiretroviral therapy? A meta-analysis of observational cohorts.

Authors:  A I Abioye; A I Soipe; A A Salako; M O Odesanya; T A Okuneye; A I Abioye; K A Ismail; M O Omotayo
Journal:  AIDS Care       Date:  2015

3.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa.

Authors:  Y D Mukadi; D Maher; A Harries
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

5.  A brief history of South Africa's response to AIDS.

Authors:  N P Simelela; W D F Venter
Journal:  S Afr Med J       Date:  2014-03

6.  Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.

Authors:  Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol
Journal:  PLoS Med       Date:  2014-11-25       Impact factor: 11.069

Review 7.  Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Sarah W Beckham; Chris Beyrer; Peter Luckow; Meg Doherty; Eyerusalem K Negussie; Stefan D Baral
Journal:  J Int AIDS Soc       Date:  2016-11-08       Impact factor: 5.396

8.  Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study.

Authors:  Leigh F Johnson; Margaret T May; Rob E Dorrington; Morna Cornell; Andrew Boulle; Matthias Egger; Mary-Ann Davies
Journal:  PLoS Med       Date:  2017-12-12       Impact factor: 11.069

Review 9.  The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.

Authors:  Anna Odone; Silvia Amadasi; Richard G White; Theodore Cohen; Alison D Grant; Rein M G J Houben
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

10.  Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa.

Authors:  Jacob Bor; Sydney Rosen; Natsayi Chimbindi; Noah Haber; Kobus Herbst; Tinofa Mutevedzi; Frank Tanser; Deenan Pillay; Till Bärnighausen
Journal:  PLoS Med       Date:  2015-11-24       Impact factor: 11.613

View more
  3 in total

1.  Early mortality during rifampicin-resistant TB treatment.

Authors:  E Mohr-Holland; J Daniels; A Reuter; C A Rodriguez; C Mitnick; Y Kock; V Cox; J Furin; H Cox
Journal:  Int J Tuberc Lung Dis       Date:  2022-02-01       Impact factor: 2.373

2.  Time trends in tuberculosis mortality across the BRICS: an age-period-cohort analysis for the GBD 2019.

Authors:  Zhiyong Zou; Guangqi Liu; Simon I Hay; Saurav Basu; Uzma Iqbal Belgaumi; Arkadeep Dhali; Sameer Dhingra; Ginenus Fekadu; Mahaveer Golechha; Nitin Joseph; Kewal Krishan; Francisco Rogerlândio Martins-Melo; Sumaira Mubarik; Osaretin Christabel Okonji; Mahesh P A; Priya Rathi; Ranjitha S Shetty; Paramdeep Singh; Surjit Singh; Pugazhenthan Thangaraju; Ziyue Wang; Mikhail Sergeevich Zastrozhin; Christopher J L Murray; Hmwe Hmwe Kyu; Yangmu Huang
Journal:  EClinicalMedicine       Date:  2022-09-17

3.  Linkage to care and treatment outcomes for patients diagnosed with drug-susceptible tuberculosis using Xpert MTB/RIF assay in Thaba-Tseka district in Lesotho.

Authors:  Nteseng Mabote; Meseret Mamo; Bienvenu Nsakala; Samson Lanje; Ntumwa R Mwanawabene; Bulemba Katende
Journal:  IJID Reg       Date:  2022-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.